Management of patients with long-term inhibitors: Is immune tolerance an underestimated life-long solution?

Haemophilia

Volumn 19, Issue SUPPL. 1, 2013, Pages 18-23

  Di Minno, G ^a   Coppola, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cost utility; Factor VIII; Haemophilia; Immune tolerance induction; Inhibitors

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTHROPATHY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG HALF LIFE; FOLLOW UP; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LONG TERM CARE; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME;

COAGULANTS; COST-BENEFIT ANALYSIS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES;

EID: 84871666717     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12052     Document Type: Review

References (42)

1. Coppola A, Di Minno MND, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
2. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
3. UK Haemophilia Centre Doctors' Organization. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
4. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
5. Gringeri A, Mannucci PM; Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-9.
6. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
7. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
8. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
9. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
10. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
11. Unuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia 2000; 6: 150-7.
12. Rocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica 2006; 91: 558-61.
13. Mariani G, Kroner B, for the Immune Tolerance Study Group. Immune tolerance in hemophilia with inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
14. Lenk H. The German registry of immune tolerance treatment in hemophilia - 1999 update. Haematologica 2000; 85: 45-7.
15. DiMichele DM, Kroner BL; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
16. Coppola A, Margaglione M, Santagostino E et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
17. Coppola A, Scaraggi F, Biasoli C et al. How many patients with high-responding inhibitors did/did not undergo immune tolerance induction in Italy? Why not? Haemophilia 2012; 18(Suppl. 3): 88.
18. Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia 2005; 11(Suppl. 1): 11-7.
19. Minno Di MN, Di Minno G, Di Capua M, Cerbone AM, Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia 2009; 16: e190-201.
20. Auerswald G, von Depka Prondzinski M, Ehlken B et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004; 10: 499-508.
21. Scharf R, Kucharski W, Nowak T. Surgery in hemophilia A patients with factor VIII inhibitor: 10-year experience. World J Surg 1996; 20: 1171-81.
22. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
23. Gringeri A, Scalone L, Mantovani L, Rocino A. Cost of immune tolerance induction in hemophilia A patients: results from the ITER study. Haemophilia 2012; 18(Suppl. 1): 15.
24. Vdovin V, Svirin P, Shiller E et al. Immune tolerance therapy in children with FVIII inhibitors: progress report. Haemophilia 2012; 18(Suppl. 1): 14.
25. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992; 14: 82-7.
26. Batlle J, Lopez MF, Brackmann HH et al. Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. Haemophilia 1999; 5: 431-5.
27. Barnes C, Rivard GE, Poon M-C et al. Canadian multiinstitutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT. Haemophilia 2006; 12: 1-6.
28. Kucharski W, Scharf R, Nowak T. Immune tolerance induction in haemophiliacs with inhibitor to FVIII: high- or low-dose programme. Haemophilia 1996; 2: 224-8.
29. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77(Suppl. 1): 33-7.
30. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
31. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
32. Gringeri A, Musso R, Mazzucconi MG et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
33. Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008; 14: 295-302.
34. Valentino LA, Recht M, Dipaola J et al. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A. Haemophilia 2009; 15: 718-26.
35. Kurth M, Puetz M, Kouides P et al. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost 2011; 9: 2229-34.
36. ®) in 14 patients with severe haemophilia A. Haemophilia 2011; 17: e837-40.
37. Franchini M, Lippi G. von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemost 2010; 104: 931-40.
38. Di Minno G, Coppola A. A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors? Blood Transfus 2011; 9(Suppl. 2): s14-20.
39. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007; 13(Suppl. 5): 73-7.
40. Coppola A, Margaglione M, Santagostino E et al. Predictors of success of immune tolerance induction in haemophilia A patients with high-responding inhibitors: a score from the Italian registry. Haemophilia 2012; 18(Suppl. 3): 85.
41. van Helden PM, Kaijen PH, Mauser-Bunschoten EP, Fischer K, van den Berg HM, Voorberg J. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A. Haemophilia 2010; 16: 892-901.
42. Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic Effectiveness of Factor VIII (FVIII) Concentrates in Patients Affected by Inherited Haemophilia A With FVIII Inhibitors High and Low Anamnestic Response. Clini0063alTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT01505946. Accessed August 3, 2012.